GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

GoodRx Holdings, Inc. (GDRX) Misses Q2 Earnings and Revenue Estimates

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $200.6 million Net income of $6.7 million; Net income margin of 3.3% Adjusted Net Income1 of $32.4 million; Adjusted Net Income Margin1 of 16.1% Adjusted EBITDA1 of $65.4 million; Adjuste.

GoodRx Reports Second Quarter 2024 Results

Besides Wall Street's top -and-bottom-line estimates for GoodRx (GDRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

Unveiling GoodRx (GDRX) Q2 Outlook: Wall Street Estimates for Key Metrics

GoodRx stock rated a sell due to industry headwinds, cost growth outpacing revenue, and needing 12%+ growth to justify price. Q2 earnings expected to be in line with guidance, but long-term guidance doesn't support current price point. Upside potential if GoodRx doubles market growth, but industry headwinds and growth struggles pose challenges.

GoodRx Q2 Earnings Preview

A close copy version of Abbvie's blockbuster arthritis drug Humira will be available at a 92% discount to its list price on the GoodRx website, the digital healthcare platform and German drugmaker Boehringer Ingelheim said on Thursday.

Boehringer-GoodRx partner to offer Humira rival at 92% discount

First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and SANTA MONICA, Calif.

Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira®

ICON

Investors with an interest in Medical Services stocks have likely encountered both Icon PLC (ICLR) and GoodRx Holdings, Inc. (GDRX). But which of these two stocks is more attractive to value investors?

ICLR vs. GDRX: Which Stock Is the Better Value Option?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its second quarter 2024 financial results before U.S. markets open on Thursday, August 8, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference.

GoodRx Announces Date for Second Quarter 2024 Earnings Release and Conference Call

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced the election of Ian T. Clark to its Board of Directors. Mr. Clark brings to GoodRx over 35 years of experience in the pharmaceutical and healthcare industries. He formerly served as Chief Executive Officer of Genentech, a biotechnology company, and previously held leadership positions at Novartis, Sanof.

Ian T. Clark Joins GoodRx Board of Directors

GameStop

A pending or ongoing lawsuit isn't always a reliable indicator of stocks to sell, but, in many cases, investors should take litigation as a sign to dig beneath the surface. I'd first caution retail investors not to take pending litigation as a sure sign of failure or risk; tons of legal firms push frivolous lawsuits in a bid to maximize their own income.

3 Lawsuit-Laden Stocks to Dump Before Problems Multiply

Affirm

Udemy

Smart money is looking for the exit as market conditions become increasingly shaky and, more often than not, they're looking at tech stocks to sell more than any other segment or sector. June's net tech stock sales are about to hit their highest monthly level since 2017 as hedge funds and institutional investors begin looking for an off-ramp from increasingly concentrated tech portfolios and indices.

Market Correction Alert: Sell These 3 Tech Stocks While You Can

The cost of prescription medications in the U.S. has increased by 37% since 2014, far surpassing the rate of inflation, according to data from drug savings company GoodRx. Though the price increases have slowed this year in comparison with the past decade, the average American spends $16.26 out of pocket per prescription, according to the data.

Drug prices have risen almost 40% over the last decade, according to a new tracker

GoodRx aims to give consumers a better handle on prescription affordability. The prescription savings platform introduced its Prescription Cost Tracker to monitor out-of-pocket prescription spending trends in the United States, according to a Wednesday (June 26) press release.

GoodRx Debuts Tracker to Monitor Out-of-Pocket Prescription Costs

SANTA MONICA, Calif.--(BUSINESS WIRE)--Today, GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., debuted its new Prescription Cost Tracker where it will monitor out-of-pocket prescription spending trends in the U.S. to help Americans better understand prescription affordability and price transparency. Helping Americans get the healthcare they need starts with tackling the barriers of costs and coverage, and there are three key factors driving the financial burden for.

GoodRx Launches New “Prescription Cost Tracker” to Spotlight Key Factors Driving Out-of-Pocket Medication Costs in the U.S.

NEW YORK, NY / ACCESSWIRE / June 21, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=86819&wire=1 or contact Joseph E. Levi, Esq.

June 21, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against GDRX

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) and reminds investors of the June 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRx

LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

Investors With Losses In GoodRx Holdings Inc Are Encouraged By The Schall Law Firm To Make Contact Before The Deadline

LOS ANGELES--(BUSINESS WIRE)--GDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

GDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--GoodRx Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GDRX.

GoodRx Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GDRX

NEW YORK , June 21, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GoodRx investors who were adversely affected by alleged securities fraud between September 23, 2020 and November 8, 2022.

Lost Money on GoodRx Holdings, Inc.(GDRX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) common stock between September 23, 2020, and November 8, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On May 9, 2022, after the market closed, GoodRx anno.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against GoodRx Holdings, Inc. (GDRX)

NEW YORK, NY / ACCESSWIRE / June 20, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=86580&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of GoodRx Holdings, Inc.(GDRX) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / June 20, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=86585&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on GoodRx Holdings, Inc.(GDRX) should contact Levi & Korsinsky about pending Class Action - GDRX

LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

The Schall Law Firm Encourages Investors Who Have Suffered Losses With GoodRx Holdings Inc To Make Contact Before The Deadline

RADNOR, PA / ACCESSWIRE / June 20, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company") on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the "Class Period"). This action, captioned Barsuli v.

News for GoodRx Holdings Stock (GDRX)